CCND1 and prostate carcinoma: In addition to downregulated AKT activity, reduced Cyclin D1 expression by AZA1 treatment fits to these findings, since evidence suggests that Rac1 affects transformation through regulation of Cyclin D1, a cell cycle protein that is frequently over-expressed in prostate cancer xenografts and metastases [51], [52].